Core Insights - VolitionRx Limited presents two studies at the European Lung Cancer Congress 2025, highlighting the potential of its Nu.Q® H3K27Me3 biomarker combined with circulating tumor DNA to enhance prognostic value for overall survival in Non-Small Cell Lung Cancer (NSCLC) [1] - The studies also showcase Volition's Nu.Q® H3.1, a low-cost immunoassay aimed at early identification of individuals at high risk for cancer [1] Group 1: Event Details - The European Lung Cancer Congress 2025 (ELCC 2025) is held in Paris, France from March 26-29, 2025 [2] - Two poster sessions are scheduled for March 28, 2025, featuring presentations on early detection and prognostic biomarkers in NSCLC [3] Group 2: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancer [4] - The company aims to develop cost-effective blood tests to enhance patient outcomes and quality of life through early detection [5] - Volition's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [6]

HENDERSON, Nev., March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer. To register, click here.This webinar will provide an overview following the completion of a number of large independent ...

Core Viewpoint - VolitionRx Limited will host a conference call on March 31, 2025, to discuss its financial and operational results for Q4 and the full fiscal year 2024, along with a business update [1][2]. Group 1: Conference Call Details - The conference call is scheduled for March 31, 2025, at 4:30 p.m. U.S. Eastern Time [1][2]. - Dial-in numbers for the call include a toll-free option for the U.S. and Canada at 1-877-407-9716, and an international toll number at 1-201-493-6779 [2]. - The call will be hosted by key executives including the Group Chief Marketing & Communications Officer, the President and Group CEO, the Group CFO, and the Chief Medical Officer [2]. Group 2: Company Overview - Volition is a multinational company focused on advancing epigenetics to improve early detection and monitoring of diseases [4][5]. - The company is developing cost-effective blood tests for various diseases, including certain cancers and conditions related to NETosis, such as sepsis [5]. - Research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [5].

Core Insights - VolitionRx Limited has developed an automated Nu.Q® Cancer test that accurately detects 21 different types of cancers with high specificity and low false positive rates, potentially serving as a standalone pan-cancer test or in conjunction with other liquid biopsy technologies [1][4][5] - The company aims to disrupt the $20 billion annual market for liquid biopsy in the U.S. by providing early cancer detection solutions [2] - Volition is in discussions with large diagnostic and liquid biopsy companies to establish multiple licensing agreements, which may include milestone payments and ongoing revenue [3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve early detection and monitoring of diseases, including cancer [6][7] - The company’s research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [8] Study Details - The study involved 229 cancer patients (including 70 early-stage patients) and 150 healthy subjects, demonstrating an overall AUC of 86% for detecting common fatal cancers such as lung, breast, prostate, colon, and liver cancers [4][5] - The Nu.Q® Cancer test is designed to be run on existing automated chemiluminescence platforms, making it accessible without the need for new hardware [4] Future Prospects - The company is focused on leveraging its existing technology to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [4] - There is potential for the Nu.Q® platform to be used not only for early cancer detection but also in the management of cancer patients, particularly in assessing treatment efficacy [5]

Core Viewpoint - VolitionRx Limited aims to transform the lung cancer diagnosis and monitoring landscape with its Nu.Q® Cancer Test, targeting the $4 billion lung cancer market [1][4]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing early detection and monitoring of diseases, including cancer [6][7]. - The company is developing cost-effective blood tests that can be administered easily, utilizing small blood samples [1][7]. Product Development - The Nu.Q® Cancer assays are designed to improve early detection and monitoring of lung cancer, potentially enhancing patient outcomes [1][3]. - A retrospective study involving 1,050 patients with Non-Small Cell Lung Cancer is set to be published, supporting the efficacy of Nu.Q® Cancer [4]. Market Opportunity - The total annual accessible market for lung cancer screening, prognostication, and minimal residual disease identification is estimated at approximately $4 billion [4]. - VolitionRx is in discussions with large diagnostics and liquid biopsy companies to establish multiple licensing agreements this year [4]. Commercial Strategy - The company's nucleosome assays can be utilized on existing automated chemiluminescence platforms, eliminating the need for new hardware [5]. - VolitionRx aims to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [5].

Core Viewpoint - VolitionRx Limited is participating as a silver sponsor at the 44th Annual ISICEM Congress in Brussels, showcasing its Nu.Q® H3.1 epigenetic screening technology, which has significant implications for sepsis care and critical care medicine [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics, dedicated to improving outcomes for patients with life-altering diseases through earlier detection and monitoring [9][10] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [10] Market Opportunity - The developments presented at ISICEM highlight a market opportunity exceeding $1 billion in sepsis care, positioning Volition at the forefront of advancements in critical care medicine [3] Presentations at ISICEM - Multiple presentations will feature the Nu.Q® H3.1 technology, including topics such as circulating NETs levels, functional endotyping in sepsis, and the role of H3.1 in early recognition of sepsis [3][4][5] - Notable speakers include Professor Djillali Annane and Professor Evangelos Giamarellos-Bourboulis, who will present on various aspects of sepsis and its management [4][5] Educational Impact - The ISICEM congress aims to enhance the care of critically ill patients through education and research, attracting over 5,000 participants globally [8]

Core Viewpoint - VolitionRx Limited has expanded its supply agreement with Fujifilm Vet Systems in Japan to include an automated version of its Nu.Q® Vet Cancer Test, aiming for a launch in summer 2025 [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for people and animals through early detection of diseases [7][8] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers [8] Product Details - The Nu.Q® Vet Cancer Test is designed for regular check-ups of older dogs (seven years and older) or younger high-risk breeds, priced at an average of $11 per test for central lab testing [4] - The test is non-invasive and aims to aid in early cancer detection, which is crucial as cancer is the leading cause of adult canine deaths [3][4] Market Opportunity - There are approximately seven million pet dogs in Japan, presenting a significant revenue opportunity for Volition through its partnership with Fujifilm Vet Systems, a leading provider of diagnostic tests in the country [2] - Since the launch of the Nu.Q® Vet Cancer Test in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test, indicating strong demand [2][3] Partnership Dynamics - Fujifilm Vet Systems will validate and verify the automated platform for canine cancer screening, enhancing the efficiency and throughput of the testing process [1][2] - The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test across its network of central reference laboratories in Japan [3]

Core Insights - VolitionRx Limited has initiated a clinical study to evaluate its Nu.Q® Cancer technology for differentiating between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer [1][5] - The study, in collaboration with National Taiwan University Hospital, aims to enroll 500 patients and is expected to be completed by the end of 2025 [1][2] - Previous studies indicate that the Nu.Q® Cancer test can accurately identify malignant nodules with high sensitivity, which could lead to its inclusion in national lung cancer screening programs [4][5] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection of diseases [8][9] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers [9] - Volition's research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [9] Industry Context - Lung cancer is a leading cause of cancer-related deaths globally, and LDCT is recognized as the gold standard for lung cancer screening [3] - The high sensitivity of LDCT can lead to false positives and unnecessary invasive procedures for patients with benign nodules, highlighting the need for more accurate diagnostic tools [3][6] - A blood-based test that can distinguish between cancerous and non-cancerous nodules would significantly enhance clinical practice and lung cancer screening programs [7]

Core Insights - VolitionRx Limited has signed an agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study, marking a significant milestone for the company [1][3] - The study is expected to generate substantial revenue for Volition over a 12-18 month period, with further projects under discussion [2] Company Developments - The Nu.Q® Discover program offers advanced assays for rapid epigenetic profiling, aiding drug developers and scientists from discovery to market readiness [1][9] - The collaboration allows Volition to leverage its nucleosome expertise to enhance clinical research, potentially improving patient selection for treatment [5][6] Market Positioning - This partnership highlights the growing recognition of Volition's nucleosome-based biomarkers in clinical development, aligning with the company's long-term goal of enabling precision therapy [4][7] - The application of Nu.Q® Discover in clinical trials positions Volition to expand its role in precision medicine and targeted therapeutic approaches [8]

Core Points - VolitionRx Limited will participate in the 97th Annual Western Veterinary Conference (WVC) from March 2-5, 2025, in Las Vegas, NV, attracting approximately 20,000 veterinary professionals [1][5] - The company will showcase its Nu.Q® Vet Cancer Test, which aids in the detection of seven common cancers in dogs, emphasizing its accessibility, affordability, and ease of use [3][4] - Volition's strategic commercialization efforts in North America aim to expand awareness and education regarding the Nu.Q® Vet Cancer Test [3] Event Details - Presentation 1: "Detect, Treat, Monitor: Navigating the Canine Cancer Journey with Nu.Q® Vet Cancer Test" by Dr. Sue Ettinger on March 3, 2025, from 2:00 PM to 2:50 PM [4] - Presentation 2: "Utilizing the Nu.Q® Vet Cancer Test in Practice" by Dr. Brett Cordes on March 4, 2025, from 10:30 AM to 11:00 AM [4] - Presentation 3: "The Nu.Q® Vet Cancer Test - Early Detection with Canine Cancer Screening" by Dr. Tom Butera on March 5, 2025, from 12:10 PM to 1:00 PM [4] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring [5][6] - The company is developing cost-effective blood tests to diagnose and monitor various diseases, including cancers and conditions associated with NETosis, such as sepsis [6][7] - Volition's research and development activities are centered in Belgium, with additional facilities in the U.S. and London [7]